|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Concerta
|
|
gptkbp:affects
|
increased energy
|
|
gptkbp:approves
|
1950s
|
|
gptkbp:brand
|
Dexedrine Spansule
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:contraindication
|
gptkb:sneaker
hyperthyroidism
cardiovascular disorders
|
|
gptkbp:discipline
|
possible
|
|
gptkbp:discontinued
|
some markets
|
|
gptkbp:duration
|
short-term
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:focus
|
increased attention
|
|
gptkbp:form
|
gptkb:tablet
extended-release capsule
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dexedrine
|
|
gptkbp:ingredients
|
gptkb:dextroamphetamine
C9 H13 N
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:is_atype_of
|
N06 B A02
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_motivated_by
|
high
|
|
gptkbp:is_part_of
|
amphetamine class
|
|
gptkbp:is_used_for
|
ADHD
narcolepsy
|
|
gptkbp:legal_issue
|
controlled substance
|
|
gptkbp:lifespan
|
10-12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
1950s
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:mood
|
euphoria
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
CNS stimulant
|
|
gptkbp:related_to
|
gptkb:Adderall
methamphetamine
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:side_effect
|
anxiety
insomnia
dry mouth
increased heart rate
loss of appetite
|
|
gptkbp:symptoms
|
gptkb:historical_event
fatigue
sleep disturbances
cardiac arrest
seizures
hallucinations
agitation
|
|
gptkbp:type_of
|
51-64-9
|